Clover Corporation Limited CLV
ASX · Australia · Health Technology
AUD 1.050.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Clover Corp Ltd (ASX:CLV) capped FY26 with record revenue of $97.4 million and a 50% jump in NPAT, as ARA momentum and a debt-free balance sheet set the stage for a stronger first half of FY27.
As Australian shares prepare for a modest rise, the local market is closely watching economic indicators such as job advertisements and building approvals, alongside international developments like U.S.-Iran peace talks. For investors considering smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing area of investment. These stocks can offer surprising value and growth potential when backed by strong financials, making them worth considering for...
Clover Corporation Limited (ASX:CLV) CEO & managing director Peter Davey talked with Proactive at the ASX Small and Mid-Cap Conference about the company’s technology-driven approach to delivering omega-3 and omega-6 nutritional solutions, and how this is supporting strong global growth. Davey explained that Clover specialises in microencapsulation technology, which allows oils such as fish, algal and fungal oils to be converted into powder form. This process removes taste and smell while preserving nutritional benefits, enabling integration into a wide range of food and beverage products. As h
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.